Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | GAA | P10253 | 4/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 6/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.38 |
| ▸ | HPGD | P15428 | 5/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | GUSB | P08236 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660519 | 0.80 | MAPT (0.55) | MAPTGAATP53KDM4ENPC1 | |
| SCHEMBL5311866 | 0.80 | TP53 (0.48) | MAPTTP53MEN1KMT2AKDM4E | |
| SCHEMBL5312981 | 0.79 | DCTPP1 (0.45) | GAAKDRMEN1KMT2AKDM4E | |
| SCHEMBL5833790 | 0.75 | KMT2A (0.52) | MAPTGAATP53MEN1KMT2A | |
| SCHEMBL5313033 | 0.74 | RAB9A (0.68) | MAPTGAATP53MEN1KMT2A | |
| SCHEMBL14668861 | 0.74 | ERN1 (0.48) | MAPTGAATP53KDRMEN1 | |
| SCHEMBL5833692 | 0.73 | WDR5 (0.53) | GAAKMT2AKDM4ENPC1RAB9A | |
| SCHEMBL4200476 | 0.70 | ATM (0.48) | MAPTGAAKDRMEN1KMT2A | |
| SCHEMBL5833461 | 0.70 | KDM4E (0.43) | MAPTTP53KDRMEN1KMT2A | |
| SCHEMBL5470984 | 0.70 | GRM5 (0.53) | KDRMEN1KMT2AKDM4EDCTPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539749-A4 | FUSED HETEROBICYCLO SUBSTITUTED PHENYL METABOTROPIC GLUTAMATE-5 MODULATORS | MERCK & CO INC (US) | 2007-06-13 | — | — | EP | disclosed |
| US-7105533-B2 | Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators | MERCK & CO., INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-20050240021-A1 | Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators | MERCK SHARP & DOHME CORP. | 2005-10-27 | — | — | US | disclosed |
| EP-1539749-A2 | FUSED HETEROBICYCLO SUBSTITUTED PHENYL METABOTROPIC GLUTAMATE-5 MODULATORS | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004024074-A2 | FUSED HETEROBICYCLO SUBSTITUTED PHENYL METABOTROPIC GLUTAMATE-5 MODULATORS | MERCK & CO., INC. (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004024074-A2 | FUSED HETEROBICYCLO SUBSTITUTED PHENYL METABOTROPIC GLUTAMATE-5 MODULATORS | MERCK & CO., INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050240021-A1 | Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators | GRM5, GRIK5, GRM1 | MAPT 1844/4885GAA 2431/4885TP53 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.